EHA Topics in focus : Immunotherapy

EHA 2018: The unmet needs in maintenance therapy for multiple myeloma

EHA 2018: Results of the OPTIMISMM trial

International cancer control plans

Updates in melanoma from ASCO 2018

What does progression-free survival mean for breast cancer patients?

Education, collaboration and communication in global cancer control

Treatment updates in Merkel cell carcinoma

Zoptarelin no better than doxarubicin for second-line advanced endometrial cancer

Immunotherapy trials and hyperprogressive disease

First-in-human phase 1 study of TAK-931 for solid tumours

Web-mediated follow-up via patient-reported outcomes vs. routine surveillance in lung cancer patients